15 results on '"Davis, Rachel L."'
Number of results to display per page
Search Results
2. Unmasking the Holder of the Purse Strings: Countering Chinese Economic Coercion in the Indo-Pacific
- Author
-
Davis, Rachel L. and Davis, Rachel L.
- Abstract
The Indo-Pacific is a key focal point of U.S.-China competition due to its geographical, economic, and military significance. China is using political warfare to achieve its strategic goals in the region, influencing other nations to align with its interests. Economic coercion is a key tool of this warfare. This is evident in the Pacific Islands, among America’s treaty allies, in Southeast Asia, and in South Asia. To prove itself the superior partner, maintain access to key points of land, and keep the Indo-Pacific open for trade, the U.S. must counter China’s activities. This can be achieved via a stronger economic strategy, deeper engagement with allies and partners, exposure of China’s illicit activities, and the development of a true grand strategy.
- Published
- 2024
3. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy
- Author
-
Rosato, Pamela C., Wijeyesinghe, Sathi, Stolley, J. Michael, Nelson, Christine E., Davis, Rachel L., Manlove, Luke S., Pennell, Christopher A., Blazar, Bruce R., Chen, Clark C., Geller, Melissa A., Vezys, Vaiva, and Masopust, David
- Published
- 2019
- Full Text
- View/download PDF
4. Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants
- Author
-
Lima, Noemia S, primary, Mukhamedova, Maryam, additional, Johnston, Timothy S, additional, Wagner, Danielle A, additional, Henry, Amy R, additional, Wang, Lingshu, additional, Yang, Eun Sung, additional, Zhang, Yi, additional, Birungi, Kevina, additional, Black, Walker P, additional, O'Dell, Sijy, additional, Schmidt, Stephen D, additional, Moon, Damee, additional, Lorang, Cynthia G, additional, Zhao, Bingchun, additional, Chen, Man, additional, Boswell, Kristin, additional, Roberts-Torres, Jesmine, additional, Davis, Rachel L, additional, Peyton, Lowrey, additional, Narpala, Sandeep R, additional, O'Connell, Sarah, additional, Wang, Jennifer, additional, Schrager, Alexander, additional, Talana, Chloe Adrienna, additional, Leung, Kwanyee, additional, Shi, Wei, additional, Khashab, Rawan, additional, Biber, Asaf, additional, Zilberman, Tal, additional, Rhein, Joshua, additional, Vetter, Sara, additional, Ahmed, Afeefa, additional, Novik, Laura, additional, Widge, Alicia, additional, Gordon, Ingelise, additional, Guech, Mercy, additional, Teng, I-Ting, additional, Phung, Emily, additional, Ruckwardt, Tracy, additional, Pegu, Amarendra, additional, Misasi, John, additional, Doria-Rose, Nicole A, additional, Gaudinski, Martin, additional, Koup, Richard A, additional, Kwong, Peter D, additional, McDermott, Adrian B, additional, Amit, Sharon, additional, Schacker, Timothy W, additional, Levy, Itzchak, additional, Mascola, John R, additional, Sullivan, Nancy J, additional, Schramm, Chaim A, additional, and Douek, Daniel C, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
- Author
-
Corbett, Kizzmekia S., primary, Gagne, Matthew, additional, Wagner, Danielle A., additional, O’ Connell, Sarah, additional, Narpala, Sandeep R., additional, Flebbe, Dillon R., additional, Andrew, Shayne F., additional, Davis, Rachel L., additional, Flynn, Barbara, additional, Johnston, Timothy S., additional, Stringham, Christopher D., additional, Lai, Lilin, additional, Valentin, Daniel, additional, Van Ry, Alex, additional, Flinchbaugh, Zackery, additional, Werner, Anne P., additional, Moliva, Juan I., additional, Sriparna, Manjari, additional, O’Dell, Sijy, additional, Schmidt, Stephen D., additional, Tucker, Courtney, additional, Choi, Angela, additional, Koch, Matthew, additional, Bock, Kevin W., additional, Minai, Mahnaz, additional, Nagata, Bianca M., additional, Alvarado, Gabriela S., additional, Henry, Amy R., additional, Laboune, Farida, additional, Schramm, Chaim A., additional, Zhang, Yi, additional, Yang, Eun Sung, additional, Wang, Lingshu, additional, Choe, Misook, additional, Boyoglu-Barnum, Seyhan, additional, Wei, Shi, additional, Lamb, Evan, additional, Nurmukhambetova, Saule T., additional, Provost, Samantha J., additional, Donaldson, Mitzi M., additional, Marquez, Josue, additional, Todd, John-Paul M., additional, Cook, Anthony, additional, Dodson, Alan, additional, Pekosz, Andrew, additional, Boritz, Eli, additional, Ploquin, Aurélie, additional, Doria-Rose, Nicole, additional, Pessaint, Laurent, additional, Andersen, Hanne, additional, Foulds, Kathryn E., additional, Misasi, John, additional, Wu, Kai, additional, Carfi, Andrea, additional, Nason, Martha C., additional, Mascola, John, additional, Moore, Ian N., additional, Edwards, Darin K., additional, Lewis, Mark G., additional, Suthar, Mehul S., additional, Roederer, Mario, additional, McDermott, Adrian, additional, Douek, Daniel C., additional, Sullivan, Nancy J., additional, Graham, Barney S., additional, and Seder, Robert A., additional
- Published
- 2021
- Full Text
- View/download PDF
6. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
- Author
-
Francica, Joseph R., primary, Flynn, Barbara J., additional, Foulds, Kathryn E., additional, Noe, Amy T., additional, Werner, Anne P., additional, Moore, Ian N., additional, Gagne, Matthew, additional, Johnston, Timothy S., additional, Tucker, Courtney, additional, Davis, Rachel L., additional, Flach, Britta, additional, O’Connell, Sarah, additional, Andrew, Shayne F., additional, Lamb, Evan, additional, Flebbe, Dillon R., additional, Nurmukhambetova, Saule T., additional, Donaldson, Mitzi M., additional, Todd, John-Paul M., additional, Zhu, Alex Lee, additional, Atyeo, Caroline, additional, Fischinger, Stephanie, additional, Gorman, Matthew J, additional, Shin, Sally, additional, Edara, Venkata Viswanadh, additional, Floyd, Katharine, additional, Lai, Lilin, additional, Boyoglu-Barnum, Seyhan, additional, Van De Wetering, Renee, additional, Tylor, Alida, additional, McCarthy, Elizabeth, additional, Lecouturier, Valerie, additional, Ruiz, Sophie, additional, Berry, Catherine, additional, Tibbitts, Timothy, additional, Andersen, Hanne, additional, Cook, Anthony, additional, Dodson, Alan, additional, Pessaint, Laurent, additional, Van Ry, Alex, additional, Koutsoukos, Marguerite, additional, Gutzeit, Cindy, additional, Teng, I.-Ting, additional, Zhou, Tongqing, additional, Li, Dapeng, additional, Haynes, Barton F., additional, Kwong, Peter D., additional, McDermott, Adrian, additional, Lewis, Mark G., additional, Fu, Tong Ming, additional, Chicz, Roman, additional, van der Most, Robbert, additional, Corbett, Kizzmekia S., additional, Suthar, Mehul S., additional, Alter, Galit, additional, Roederer, Mario, additional, Sullivan, Nancy J., additional, Douek, Daniel C., additional, Graham, Barney S., additional, Casimiro, Danilo, additional, and Seder, Robert A., additional
- Published
- 2021
- Full Text
- View/download PDF
7. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
- Author
-
Wang, Lingshu, primary, Zhou, Tongqing, additional, Zhang, Yi, additional, Yang, Eun Sung, additional, Schramm, Chaim A., additional, Shi, Wei, additional, Pegu, Amarendra, additional, Oloniniyi, Olamide K., additional, Henry, Amy R., additional, Darko, Samuel, additional, Narpala, Sandeep R., additional, Hatcher, Christian, additional, Martinez, David R., additional, Tsybovsky, Yaroslav, additional, Phung, Emily, additional, Abiona, Olubukola M., additional, Antia, Avan, additional, Cale, Evan M., additional, Chang, Lauren A., additional, Choe, Misook, additional, Corbett, Kizzmekia S., additional, Davis, Rachel L., additional, DiPiazza, Anthony T., additional, Gordon, Ingelise J., additional, Hait, Sabrina Helmold, additional, Hermanus, Tandile, additional, Kgagudi, Prudence, additional, Laboune, Farida, additional, Leung, Kwanyee, additional, Liu, Tracy, additional, Mason, Rosemarie D., additional, Nazzari, Alexandra F., additional, Novik, Laura, additional, O’Connell, Sarah, additional, O’Dell, Sijy, additional, Olia, Adam S., additional, Schmidt, Stephen D., additional, Stephens, Tyler, additional, Stringham, Christopher D., additional, Talana, Chloe Adrienna, additional, Teng, I-Ting, additional, Wagner, Danielle A., additional, Widge, Alicia T., additional, Zhang, Baoshan, additional, Roederer, Mario, additional, Ledgerwood, Julie E., additional, Ruckwardt, Tracy J., additional, Gaudinski, Martin R., additional, Moore, Penny L., additional, Doria-Rose, Nicole A., additional, Baric, Ralph S., additional, Graham, Barney S., additional, McDermott, Adrian B., additional, Douek, Daniel C., additional, Kwong, Peter D., additional, Mascola, John R., additional, Sullivan, Nancy J., additional, and Misasi, John, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates
- Author
-
Corbett, Kizzmekia S., primary, Gagne, Matthew, additional, Wagner, Danielle A., additional, Connell, Sarah O’, additional, Narpala, Sandeep R., additional, Flebbe, Dillon R., additional, Andrew, Shayne F., additional, Davis, Rachel L., additional, Flynn, Barbara, additional, Johnston, Timothy S., additional, Stringham, Christopher, additional, Lai, Lilin, additional, Valentin, Daniel, additional, Van Ry, Alex, additional, Flinchbaugh, Zackery, additional, Werner, Anne P., additional, Moliva, Juan I., additional, Sriparna, Manjari, additional, O’Dell, Sijy, additional, Schmidt, Stephen D., additional, Tucker, Courtney, additional, Choi, Angela, additional, Koch, Matthew, additional, Bock, Kevin W., additional, Minai, Mahnaz, additional, Nagata, Bianca M., additional, Alvarado, Gabriela S., additional, Henry, Amy R., additional, Laboune, Farida, additional, Schramm, Chaim A., additional, Zhang, Yi, additional, Wang, Lingshu, additional, Choe, Misook, additional, Boyoglu-Barnum, Seyhan, additional, Shi, Wei, additional, Lamb, Evan, additional, Nurmukhambetova, Saule T., additional, Provost, Samantha J., additional, Donaldson, Mitzi M., additional, Marquez, Josue, additional, Todd, John-Paul M., additional, Cook, Anthony, additional, Dodson, Alan, additional, Pekosz, Andrew, additional, Boritz, Eli, additional, Ploquin, Aurélie, additional, Doria-Rose, Nicole, additional, Pessaint, Laurent, additional, Andersen, Hanne, additional, Foulds, Kathryn E., additional, Misasi, John, additional, Wu, Kai, additional, Carfi, Andrea, additional, Nason, Martha C., additional, Mascola, John, additional, Moore, Ian N., additional, Edwards, Darin K., additional, Lewis, Mark G., additional, Suthar, Mehul S., additional, Roederer, Mario, additional, McDermott, Adrian, additional, Douek, Daniel C., additional, Sullivan, Nancy J., additional, Graham, Barney S., additional, and Seder, Robert A., additional
- Published
- 2021
- Full Text
- View/download PDF
9. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
- Author
-
Francica, Joseph R., primary, Flynn, Barbara J., additional, Foulds, Kathryn E., additional, Noe, Amy T., additional, Werner, Anne P., additional, Moore, Ian N., additional, Gagne, Matthew, additional, Johnston, Timothy S., additional, Tucker, Courtney, additional, Davis, Rachel L., additional, Flach, Britta, additional, O’Connell, Sarah, additional, Andrew, Shayne F., additional, Lamb, Evan, additional, Flebbe, Dillon R., additional, Nurmukhambetova, Saule T., additional, Donaldson, Mitzi M., additional, Todd, John-Paul M., additional, Zhu, Alex Lee, additional, Atyeo, Caroline, additional, Fischinger, Stephanie, additional, Gorman, Matthew J, additional, Shin, Sally, additional, Edara, Venkata Viswanadh, additional, Floyd, Katharine, additional, Lai, Lilin, additional, Tylor, Alida, additional, McCarthy, Elizabeth, additional, Lecouturier, Valerie, additional, Ruiz, Sophie, additional, Berry, Catherine, additional, Tibbitts, Timothy, additional, Andersen, Hanne, additional, Cook, Anthony, additional, Dodson, Alan, additional, Pessaint, Laurent, additional, Ry, Alex Van, additional, Koutsoukos, Marguerite, additional, Gutzeit, Cindy, additional, Teng, I-Ting, additional, Zhou, Tongqing, additional, Li, Dapeng, additional, Haynes, Barton F., additional, Kwong, Peter D., additional, McDermott, Adrian, additional, Lewis, Mark G., additional, Fu, Tong Ming, additional, Chicz, Roman, additional, van der Most, Robbert, additional, Corbett, Kizzmekia S., additional, Suthar, Mehul S., additional, Alter, Galit, additional, Roederer, Mario, additional, Sullivan, Nancy J., additional, Douek, Daniel C., additional, Graham, Barney S., additional, Casimiro, Danilo, additional, and Seder, Robert A., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Surgical excision of iridociliary tumors using a postero‐anterior cyclo‐iridectomy and thermocautery in two dogs
- Author
-
Davis, Rachel L., primary, Reilly, Christopher M., additional, and Moore, Phillip A., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Virus-specific memory T cells populate tumors and can be repurposed as a tumor immunotherapy
- Author
-
Rosato, Pamela, primary, Wijeyesinghe, Sathi, additional, Stolley, Michael, additional, Nelson, Christine, additional, Davis, Rachel L, additional, Manlove, Luke S, additional, Pennell, Christopher A, additional, Blazar, Bruce R., additional, Chen, Clark C, additional, Geller, Melissa A, additional, Vezys, Vaiva, additional, and Masopust, David, additional
- Published
- 2019
- Full Text
- View/download PDF
12. Abstract B182: Repurposing antiviral T-cells to fight tumors
- Author
-
Rosato, Pamela C., primary, Wijeyesinghe, Sathi, additional, Stolley, J. Michael, additional, Nelson, Christine, additional, Davis, Rachel L., additional, Manlove, Luke S., additional, Pennell, Christopher A., additional, Blazar, Bruce R., additional, Chen, Clark C., additional, Geller, Melissa A., additional, Vezys, Vaiva, additional, and Masopust, David, additional
- Published
- 2019
- Full Text
- View/download PDF
13. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones.
- Author
-
Lima NS, Musayev M, Johnston TS, Wagner DA, Henry AR, Wang L, Yang ES, Zhang Y, Birungi K, Black WP, O'Dell S, Schmidt SD, Moon D, Lorang CG, Zhao B, Chen M, Boswell KL, Roberts-Torres J, Davis RL, Peyton L, Narpala SR, O'Connell S, Wang J, Schrager A, Talana CA, Leung K, Shi W, Khashab R, Biber A, Zilberman T, Rhein J, Vetter S, Ahmed A, Novik L, Widge A, Gordon I, Guech M, Teng IT, Phung E, Ruckwardt TJ, Pegu A, Misasi J, Doria-Rose NA, Gaudinski M, Koup RA, Kwong PD, McDermott AB, Amit S, Schacker TW, Levy I, Mascola JR, Sullivan NJ, Schramm CA, and Douek DC
- Abstract
An important consequence of infection with a SARS-CoV-2 variant is protective humoral immunity against other variants. The basis for such cross-protection at the molecular level is incompletely understood. Here we characterized the repertoire and epitope specificity of antibodies elicited by Beta, Gamma and ancestral variant infection and assessed their cross-reactivity to these and the more recent Delta and Omicron variants. We developed a high-throughput approach to obtain immunoglobulin sequences and produce monoclonal antibodies for functional assessment from single B cells. Infection with any variant elicited similar cross-binding antibody responses exhibiting a remarkably conserved hierarchy of epitope immunodominance. Furthermore, convergent V gene usage and similar public B cell clones were elicited regardless of infecting variant. These convergent responses despite antigenic variation may represent a general immunological principle that accounts for the continued efficacy of vaccines based on a single ancestral variant., Competing Interests: Competing interests None declared.
- Published
- 2022
- Full Text
- View/download PDF
14. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.
- Author
-
Corbett KS, Gagne M, Wagner DA, Connell SO, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham C, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Wang L, Choe M, Boyoglu-Barnum S, Shi W, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, and Seder RA
- Abstract
Neutralizing antibody responses gradually wane after vaccination with mRNA-1273 against several variants of concern (VOC), and additional boost vaccinations may be required to sustain immunity and protection. Here, we evaluated the immune responses in nonhuman primates that received 100 µg of mRNA-1273 vaccine at 0 and 4 weeks and were boosted at week 29 with mRNA-1273 (homologous) or mRNA-1273.β (heterologous), which encompasses the spike sequence of the B.1.351 (beta or β) variant. Reciprocal ID
50 pseudovirus neutralizing antibody geometric mean titers (GMT) against live SARS-CoV-2 D614G and the β variant, were 4700 and 765, respectively, at week 6, the peak of primary response, and 644 and 553, respectively, at a 5-month post-vaccination memory time point. Two weeks following homologous or heterologous boost β-specific reciprocal ID50 GMT were 5000 and 3000, respectively. At week 38, animals were challenged in the upper and lower airway with the β variant. Two days post-challenge, viral replication was low to undetectable in both BAL and nasal swabs in most of the boosted animals. These data show that boosting with the homologous mRNA-1273 vaccine six months after primary immunization provides up to a 20-fold increase in neutralizing antibody responses across all VOC, which may be required to sustain high-level protection against severe disease, especially for at-risk populations., One-Sentence Summary: mRNA-1273 boosted nonhuman primates have increased immune responses and are protected against SARS-CoV-2 beta infection.- Published
- 2021
- Full Text
- View/download PDF
15. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.
- Author
-
Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Ry AV, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, and Seder RA
- Abstract
Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike trimers (preS dTM) from the severe acute respiratory syndrome coronavirus (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHP). Binding and functional neutralization assays and systems serology revealed that NHP developed AS03-dependent multi-functional humoral responses that targeted multiple spike domains and bound to a variety of antibody F
C receptors mediating effector functions in vitro . Pseudovirus and live virus neutralizing IC50 titers were on average greater than 1000 and significantly higher than a panel of human convalescent sera. NHP were challenged intranasally and intratracheally with a high dose (3×106 PFU) of SARS-CoV-2 (USA-WA1/2020 isolate). Two days post-challenge, vaccinated NHP showed rapid control of viral replication in both the upper and lower airways. Notably, vaccinated NHP also had increased spike-specific IgG antibody responses in the lung as early as 2 days post challenge. Moreover, vaccine-induced IgG mediated protection from SARS-CoV-2 challenge following passive transfer to hamsters. These data show that antibodies induced by the AS03-adjuvanted preS dTM vaccine are sufficient to mediate protection against SARS-CoV-2 and support the evaluation of this vaccine in human clinical trials., Competing Interests: Declaration of interests All authors have declared the following interests: VL, TB, CB, SR, TMF, DC, RC are Sanofi Pasteur employees and may hold stock. MK, RvdM, and CG are employees of the GSK group of companies and report ownership of GSK shares.- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.